MedTrace Logo

Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L

NCT02232490 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2019-02-26

No results posted yet for this study

Summary

Phase III, randomized, placebo-controlled, double-blinded trial aimed to seek the therapeutic benefit of hepcortespenlisimut-L (Hepko-V5) in subjects with advanced hepatocellular carcinoma.

Conditions

Interventions

BIOLOGICAL

hepcortespenlisimut-L

hepcortespenlisimut-L (V5) is given in experimental arm

BIOLOGICAL

Placebo

Sponsors & Collaborators

  • Immunitor LLC

    lead INDUSTRY

Principal Investigators

  • aldar bourinbaiar · Immunitor LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2019-11-30
Completion
2019-12-31

Countries

  • Mongolia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02232490 on ClinicalTrials.gov